Thirty per cent of all colorectal tumours develop in the rectum. The location of the rectum
within the bony pelvis and its proximity to vital structures presents significant therapeutic …

Single agent checkpoint inhibitor therapy has not been effective for most gastrointestinal
solid tumors, but combination therapy with drugs targeting additional immunosuppressive …

Local recurrence after resection for rectal cancer remains common despite growing
acceptance that inadequate local excision may be implicated. In a prospective study of 190 …

Cancer remains one of the deadliest diseases, and its effective diagnosis and treatment
remains challenging; therefore, progress in earlier detection and improved therapeutics are …

The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation
(nCRT) followed by radical surgery. Response to nCRT varies among patients and …

Tumor sidedness has emerged as an important prognostic and predictive factor in the
treatment of colorectal cancer. Recent studies demonstrate that patients with advanced right …

Introduction Although optimising rectal cancer treatment has reduced local recurrence rates,
many patients develop distant metastases (DM). The current study investigated whether a …

Sporadic and inflammatory forms of colorectal cancer (CRC) account for more than 80% of
cases. Recent publications have shown mechanistic evidence for the involvement of gut …

Colon cancer stem cells (CSC) identified by cell surface markers CD133, CD24, and CD44,
have been shown to be involved with tumor formation, chemotherapy resistance, and the …

Background The group of colorectal cancer (CRC) survivors continues to grow worldwide.
Understanding health-related quality of life (HRQOL) determinants and consequences of …